Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) kicked off on Friday, down -6.38% from the previous trading day, before settling in for the closing price of $19.75. Over the past 52 weeks, ARWR has traded in a range of $17.05-$39.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.87% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 49.64%. With a float of $115.84 million, this company’s outstanding shares have now reached $124.38 million.
In an organization with 609 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -282.15%, operating margin of -16927.06%, and the pretax margin is -17247.54%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 6.76%, while institutional ownership is 76.65%. The most recent insider transaction that took place on Jan 06 ’25, was worth 648,824. In this transaction Chief Discovery/Trans Medicine of this company sold 32,729 shares at a rate of $19.82, taking the stock ownership to the 272,122 shares. Before that another transaction happened on Jan 06 ’25, when Company’s COO and General Counsel sold 29,184 for $19.82, making the entire transaction worth $578,539. This insider now owns 535,201 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.64% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 6.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 648.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.00, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -3.39 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.59 million. That was better than the volume of 1.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.38%. Additionally, its Average True Range was 1.22.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 13.99%, which indicates a significant decrease from 14.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.11% in the past 14 days, which was lower than the 65.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.91, while its 200-day Moving Average is $23.15. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $19.23. Second resistance stands at $19.98. The third major resistance level sits at $20.54. If the price goes on to break the first support level at $17.92, it is likely to go to the next support level at $17.36. Assuming the price breaks the second support level, the third support level stands at $16.61.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 2.30 billion has total of 124,434K Shares Outstanding. Its annual sales at the moment are 3,550 K in contrast with the sum of -599,490 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -170,540 K.
